• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human Serpin E1/PAI-1 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3798

Validation Data Gallery

  • Purity of Recombinant Human Serpin E1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human Serpin E1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human Serpin E1 protein Val24-Pro402 (Accession# P05121-1) with a rabbit IgG Fc tag at the N-terminus.
GeneID 5054
Accession P05121-1
PredictedSize 70.0 kDa
SDS-PAGE 65-75 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

SERPINE1, also named as Plasminogen activator inhibitor type 1 (PAI-1), is a member of the serine protease inhibitor (SERPIN) superfamily. It is produced by the vascular endothelium, the liver, the monocytes/macrophagues, the platelets and the adipose tissue. High plasma levels of PAI-1 have been associated with an increased risk of suffering cardiovascular diseases. It is implicated in the pathogenesis of obesity, insulin resistance and type 2 diabetes. In several tumor types, SERPINE1 expression is up-regulated and it has been described as a poor prognostic marker. Besides its prognostic value, SERPINE1 expression has been validated as a marker for therapy decision making in patients with node-negative breast cancer. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia.

References:

1. Huang J. et al.(2012). Blood. 20: 4873-81.
2. Kohler HP. et al. (2000). N Engl J Med. 342: 1792-801.
3. Festa A. et al. (2006). Circulation. 113: 1753-9.
4. Look MP. et al. (2002). J Natl Cancer Inst. 16;94(2):116-28.
5. Ulisse S. et al. (2009). Curr Cancer Drug Targets. 9(1):32-71.